Akums Drugs & Pharmaceuticals Ltd
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
- Market Cap ₹ 9,564 Cr.
- Current Price ₹ 608
- High / Low ₹ 1,176 / 527
- Stock P/E
- Book Value ₹ 142
- Dividend Yield 0.00 %
- ROCE -14.3 %
- ROE -69.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 75.7 to 59.1 days.
Cons
- Stock is trading at 4.28 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -36.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Smallcap 250 Nifty Total Market Nifty 500 Multicap 50:25:25 BSE IPO Nifty MidSmallcap 400
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 683 | 737 | 837 | 1,162 | 1,287 | 1,444 | |
| 603 | 697 | 811 | 1,524 | 1,089 | 1,571 | |
| Operating Profit | 80 | 40 | 27 | -362 | 198 | -127 |
| OPM % | 12% | 5% | 3% | -31% | 15% | -9% |
| 58 | 66 | -195 | 58 | -4 | 75 | |
| Interest | 4 | 4 | 1 | 4 | 13 | 18 |
| Depreciation | 23 | 25 | 26 | 28 | 30 | 33 |
| Profit before tax | 112 | 76 | -195 | -335 | 150 | -103 |
| Tax % | 33% | 33% | -26% | 14% | 17% | 61% |
| 75 | 51 | -145 | -382 | 125 | -165 | |
| EPS in Rs | 636.94 | 391.05 | -1,118.18 | -53.37 | 8.77 | -11.56 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 20% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -170% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -37% |
| Last Year: | -69% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 14 | 29 | 29 | 31 |
| Reserves | 841 | 711 | 566 | 171 | 283 | 115 | 2,204 |
| 51 | 36 | 41 | 140 | 188 | 267 | 137 | |
| 153 | 678 | 690 | 1,488 | 1,395 | 1,684 | 327 | |
| Total Liabilities | 1,046 | 1,426 | 1,298 | 1,814 | 1,894 | 2,095 | 2,699 |
| 220 | 242 | 244 | 253 | 272 | 317 | 316 | |
| CWIP | 0 | 1 | 1 | 1 | 16 | 9 | 18 |
| Investments | 4 | 65 | 149 | 141 | 139 | 139 | 139 |
| 822 | 1,118 | 903 | 1,419 | 1,466 | 1,631 | 2,225 | |
| Total Assets | 1,046 | 1,426 | 1,298 | 1,814 | 1,894 | 2,095 | 2,699 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| -22 | 56 | 228 | 94 | |||
| -242 | -100 | -298 | -202 | |||
| 302 | 3 | 95 | 90 | |||
| Net Cash Flow | 38 | -42 | 25 | -18 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 85 | 88 | 92 | 95 | 73 | 59 |
| Inventory Days | 93 | 96 | 67 | 85 | 91 | 68 |
| Days Payable | 60 | 85 | 63 | 120 | 82 | 69 |
| Cash Conversion Cycle | 118 | 99 | 96 | 61 | 82 | 58 |
| Working Capital Days | 103 | 138 | 100 | 37 | 40 | 43 |
| ROCE % | 10% | 8% | -71% | 74% | -14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
2d - Long-term CDMO agreement for European market worth Euro 200 million.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
17 Dec - Voting results of Postal Ballot and Scrutinizer's report.
-
Submission Of Additional Details As Per SEBI Circular No. SEBI/HO/CFD/Cfdpod-1/P/CIR/2023/123 Dated 13Th July 2023 On Our Disclosure Dated 19Th November, 24 On Execution Of Exclusive Master Sales Agreement With Caregen Co., Ltd.
26 Nov - Akums enters exclusive sales agreement with Caregen for India.
-
Akums Exclusively Ties Up With Jagdale For Marketing Of Ready-To-Drink Nutritional Beverages In Aseptic Carton Technology
26 Nov - Akums partners with Jagdale for RTD beverages.
-
Execution Of Exclusive Master Sales Agreement With Caregen Co., Ltd ('Caregen')
19 Nov - Akums enters exclusive sales agreement with Caregen.
Concalls
-
Nov 2024Transcript PPT
-
Sep 2024Transcript PPT REC
-
Nov 2023TranscriptNotesPPTREC
Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.